MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwire - January 10, 2013) -
MorphoSys AG /
MorphoSys Completes Sale of AbD Serotec to Bio-Rad
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today
sale of its research and diagnostic antibody segment AbD Serotec to
Laboratories, Inc. (NYSE: BIO and BIOb) has been completed. All
liabilities of the AbD Serotec segment of MorphoSys AG as well as all
the subsidiaries MorphoSys UK Ltd., MorphoSys AbD GmbH and MorphoSys US,
have been transferred to Bio-Rad.
"We are delighted to have reached the closing of the transaction just
weeks after the announcement was made. With the divestment of AbD
completed, MorphoSys can devote 100% of its attention to building value
core therapeutics business," commented Jens Holstein, Chief Financial
MorphoSys developed HuCAL, the most successful antibody library
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®),
CysDisplay(®), RapMAT(®), arYla(®)
and Ylanthia(®) and 100 billion high potentials(®) are
registered trademarks of
Slonomics(®) is a registered trademark of Sloning BioTechnology
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE